Dynamics of Epstein-Barr virus in HIV-1-infected subjects on highly active antiretroviral therapy

AIDS

Volumn 16, Issue 1, 2002, Pages 63-73

  Righetti, Elisabetta ^a   Ballon, Gianna ^a   Ometto, Lucia ^a   Cattelan, Anna Maria ^a   Menin, Chiara ^a   Zanchetta, Marisa ^a   Chieco Bianchi, Luigi ^a   De Rossi, Anita ^a  

^a AIDS Reference Center   (Italy)

Author keywords

Antiretroviral therapy; EBV related non Hodgkin's lymphoma; Epstein Barr virus; HIV 1; Real time PCR

Indexed keywords

LATENT MEMBRANE PROTEIN 1; VIRUS DNA;

ADULT; AGED; ARTICLE; B LYMPHOCYTE; CLINICAL ARTICLE; EPSTEIN BARR VIRUS; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; LYMPHOCYTE COUNT; MALE; MIXED INFECTION; NONHODGKIN LYMPHOMA; PERIPHERAL LYMPHOCYTE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; T LYMPHOCYTE; VIREMIA; VIRUS INFECTION; VIRUS INHIBITION; VIRUS LOAD;

ADULT; AGED; ANTIBODIES, VIRAL; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; DNA, VIRAL; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; HERPESVIRUS 4, HUMAN; HIV INFECTIONS; HIV-1; HUMANS; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; VIRAL LOAD; VIRAL MATRIX PROTEINS;

EID: 0037016480     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200201040-00009     Document Type: Article

References (56)

1. Overview of the epidemiology of immunodeficiency-associated cancers
2. AIDS-related malignancies
3. Epstein-Barr virus-associated non-Hodgkin's lymphoma in patients infected with the human immunodeficiency virus
4. Molecular profile of Epstein-Barr virus in human immunodeficiency virus type 1-related lymphadenopathies and lymphomas
5. Pathogenesis of AIDS-related lymphomas: Molecular and histogenetic heterogeneity
6. Direct visualization of antigen-specific CD8+ T cells during the primary immune response to Epstein-Barr virus in vivo
7. Measurement by the polymerase chain reaction of the Epstein-Barr virus load in infectious mononucleosis and AIDS-related non-Hodgkin's lymphomas
8. Epstein-Barr virus DNA in the blood of infants, young children, and adults by age and HIV status
9. Epstein-Barr virus in benign lymph node biopsies from individuals infected with the human immunodeficiency virus is associated with concurrent or subsequent development of non-Hodgkin's lymphoma
10. Molecular pathogenesls of AIDS-related lymphomas
11. Epstein-Barr virus-specific cytotoxic T cell responses in HIV-1 infection: Different kinetics in patients progressing to opportunistic infection or non-Hodgkin's lymphoma
12. Restoration of the immune system with anti-retroviral therapy
13. Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults
14. Complete remission of AIDS-related Kaposi's sarcoma associated with undetectable human herpesvirus-8 sequences during anti-HIV protease therapy
15. Clinical and biological impact of antiretroviral therapy with protease inhibitors on HIV-related Kaposi's sarcoma
16. Regression of AIDS-related Kaposi's sarcoma associated with clearance of human herpes-virus-8 from peripheral blood mononuclear cells following initiation of antiretroviral therapy
17. Regression of AIDS-related Kaposi's sarcoma following antiretroviral therapy with protease inhibitors: Biological correlates of clinical outcome
18. AIDS-associated non-Hodgkin's lymphoma in the era of highly active antiretroviral therapy
19. Impact of potent antiretroviral therapy on the incidence of Kaposi's sarcoma and non-Hodgkin's lymphomas among HIV-1-infected individuals. Multicenter AIDS Cohort Study
20. Antiretroviral therapy for HIV infection in 1998: Updated recommendations of the International AIDS Society-USA Panel
21. Antiretroviral therapy in adults: Updated recommendations of the International AIDS Society-USA Panel
22. Real time quantitative PCR
23. Sensitive, high-resolution chromatin and chromosome mapping in situ: Presence and orientation of two closely integrated copies of EBV in a lymphoma line
24. B-cell activation and HIV-1 infection: Deeds and misdeeds
25. B-cell stimulation and prolonged immune deficiency are risk factors for non-Hodgkin's lymphoma in people with AIDS
26. Epstein-Barr virus latent membrane protein 1 is essential for B-lymphocyte growth transformation
27. In situ demonstration of Epstein-Barr virus small RNAs (EBER1) in acquired immunodeficiency syndrome-related lymphomas: Correlation with tumor morphology and primary site
28. Characteristics of EBV-infected cells in HIV-related lymphadenopathy: Implications for the pathogenesis of EBV-associated and EBV-unrelated lymphomas of HIV-seropositive individuals
29. Epstein-Barr virus latency in blood mononuclear cells: Analysis of viral gene transcription during primary infection and in the carrier state
30. Sequence variation in the Epstein-Barr virus latent membrane protein 1
31. Changes in the dominant Epstein-Barr virus type during human immunodeficiency virus infection
32. Analysis of Epstein-Barr virus (EBV) type and variant in spontaneous lymphoblastoid cells and Hu-SCID mouse tumours
33. Loss of cytomegalovirus (CMV) viraemia following highly active antiretroviral therapy in the absence of specific anti-CMV therapy
34. Epstein-Barr virus-infected resting memory B cells, not proliferating lymphoblasts, accumulate in the peripheral blood of immunosuppressed patients
35. HIV-1 antigen-specific and -nonspecific B cell responses are sensitive to combination antiretroviral therapy
36. Beneficial effect of highly active antiretroviral therapy (HAART) in reducing both HIV viral load and monoclonal gammopathy
37. Immunoreconstitution after ritonavir therapy in children with human immunodeficiency virus infection involves multiple lymphocyte lineages
38. Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: Results of AIDS Clinical Trials Group Protocol 315
39. Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: A composite of redistribution and proliferation
40. Frequency of multiple Epstein-Barr virus infections in T-cell-immunocompromised individuals
41. Novel immunoblot assay using four recombinant antigens for diagnosis of Epstein-Barr virus primary infection and reactivation
42. Detection of the latent form of Epstein-Barr virus DNA in the peripheral blood of healthy individuals
43. The expression pattern of Epstein-Barr virus latent genes in vivo is dependent upon the differentiation stage of the infected B cell
44. Detection of Epstein-Barr virus DNA in sera from transplant recipients with lymphoproliferative disorders
45. Detection of Epstein-Barr virus DNA in plasma from patients with lymphoproliferative disease after allogeneic bone marrow or peripheral blood stem cell transplantation
46. Quantitative and temporal correlation between circulating cell-free Epstein-Barr virus DNA and tumor recurrence in nasopharyngeal carcinoma
47. Expression of Epstein-Barr virus replicative proteins in AIDS-related non-Hodgkin's lymphoma cells
48. High Epstein-Barr virus serum load and elevated titers of anti-Zebra antibodies in patients with EBV-harboring tumor cells of Hodgkin's disease
49. Lytic replication of viral gene expression in B lymphocytes during infectious mononucleosis and in the normal carrier state
50. Predictive value of Epstein-Barr virus genome copy number and BZLF1 expression in blood lymphocytes of transplant recipients at risk for lympho-proliferative disease
51. Induction of bcl-2 expression by Epstein-Barr virus latent membrane protein 1 protects infected B cells from programmed cell death
52. The Epstein-Barr virus LMP1 gene product induces A20 zinc finger protein expression by activating nuclear factor kB
53. Epstein-Barr virus latent membrane protein 1 blocks p53-mediated apoptosis through the induction of the A20 gene
54. Identification of cytotoxic T cell epitopes within Epstein-Barr virus (EBV) oncogene latent membrane protein 1 (LMP1): Evidence for HLA A2 supertype-restricted immune recognition of EBV-infected cells by LMP1-specific cytotoxic T lymphocytes
55. Clinical and immunologic response without decrease in virus load in patients with AIDS after 24 months of highly active antiretroviral therapy
56. Dissociation of immunologic and virologic responses to highly active antiretroviral therapy